SiPhox Health’s silicon photonics chip enables 62 biomarkers from a single blood drop

How a Millimeter of Silicon Replaces a Basement of Optics

SiPhox Health has compressed a refrigerator-sized diagnostic machine — lasers, lenses, mirrors, and precision optics — onto a sliver of silicon one millimeter across. The Burlington, Massachusetts company emerged from MIT when researchers Diedrik Vermeulen and Michael Dubrovsky recognized that photonics infrastructure built for telecommunications could be repurposed for diagnostics. Their chip now targets that many biomarkers from a single blood sample, with FDA clearance being pursued, as SiPhox faces competitive pressure from Everlywell and LetsGetChecked.

Vermeulen had spent years in MIT's Silicon Photonics Group within the Research Laboratory of Electronics. Dubrovsky worked in the MIT Materials for Micro and Nano Systems group. They met through the MIT ecosystem in 2019, refined their approach at the Martin Trust Center for MIT Entrepreneurship, and entered the START.nano program for access to MIT.nano's fabrication facilities. By February 2020 they were filing patents. The pandemic arrived weeks later and forced a decision: pivot from general-purpose photonic circuits to biosensing. "We decided to focus on biosensing, with one of our chips being disposable and the other reusable," Vermeulen said.

The architecture is straightforward. Each disposable cartridge holds an array of photonic immunoassay sensors, surface-chemistry zones that bind specific proteins or hormones. Light from a semiconductor laser travels through the chip's integrated waveguides, interrogating each sensor in sequence. The reusable reader, roughly the size of a coffee maker, houses the laser, detectors, and fluidics. A third-party arm patch collects the blood. The user inserts the cartridge, presses a button, and waits. MIT News reported in November 2024 that the system produces precise readings for 20 biomarkers; the company's own specifications now cite up to 62 across nine health categories including cardiovascular, hormonal, metabolic, and inflammatory panels.

What makes the approach manufacturable is the substrate. Silicon photonics leverages the same CMOS fabs that churn out microprocessors. The founders say a single traditional fab could produce 1 billion chips per month, enough to supply every adult in the United States three times over. Their Burlington facility currently turns out roughly 10,000 cartridges monthly, a fraction of that theoretical ceiling but enough for clinical validation studies. The per-unit cost drops low enough to make the cartridge genuinely disposable, a prerequisite for consumer adoption.

TechCrunch reported that Intel Capital led a $27 million Series A in July 2023, with Khosla Ventures, Kortex Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings, and Duke Capital Partners participating. Intel Capital managing director Srini Ananth joined the board, citing the decades of datacom photonics investment that now enable "new frontiers." That capital infusion funds the engineering expansion required to bridge prototype and regulated product.

Scaling Toward Regulatory Submission

The Series A closed as the Burlington facility reached a manufacturing cadence of roughly 10,000 cartridges per month. The MIT News profile noted SiPhox was preparing to begin FDA validation studies "in coming months," a milestone that typically triggers increased headcount across quality systems, regulatory affairs, and process engineering.

A photonic chip that integrates lenses, polarizers, modulators, and splitters onto a single-millimeter die requires optical engineers who can translate benchtop alignment into wafer-level process control. Vermeulen emphasized that silicon photonics scales like semiconductors, not like assembled instruments: "There are only two ways to really scale something: You can do injection molding... But if you want to scale something very complex, you have to put it on a silicon chip." The Burlington site implies a cleanroom operation that must be qualified under FDA's Quality System Regulation (21 CFR Part 820), which in turn demands quality engineers, validation specialists, and a regulatory team that can compile a submission.

No public job board data for SiPhox appears in first-party listings. But the investor-backed timeline is explicit: pivotal studies are planned to begin in the near term. In diagnostics, that window typically corresponds to significant technical headcount growth. Companies moving from CLIA-lab services (SiPhox currently provides mail-in blood testing to thousands of people using approved technology, both directly and through other health care and wellness businesses) to an FDA-cleared, over-the-counter device add roles in biocompatibility testing, human factors engineering, cybersecurity for connected devices, and post-market surveillance.

The commercial plan Vermeulen described, partnering with health systems, insurers, employers, and mail-in blood testing companies after clearance, also implies a build-out in market access, health economics, and clinical affairs. Those functions usually hire well before launch to generate the evidence packages payers require.

FDA Clearance: The De Novo Pathway

SiPhox's pursuit of FDA clearance for a first-of-kind silicon photonics platform measuring up to 62 biomarkers from a home-collected sample is ambitious. The agency classifies multi-analyte home-use diagnostic systems as Class II or Class III devices depending on intended use and risk profile — a determination that dictates whether SiPhox pursues a 510(k) substantial equivalence pathway or a De Novo classification request. No predicate device exists for a photonic chip performing multiplexed immunoassays at home, which pushes the company toward De Novo: a longer, evidence-heavy route requiring analytical and clinical validation studies that demonstrate safety and effectiveness in untrained users' hands.

The FDA's Center for Devices and Radiological Health applies special controls to home-use tests beyond standard lab-developed test requirements. These include human factors engineering studies proving lay users can collect adequate blood volumes, follow workflow steps, and interpret results without clinical supervision. SiPhox's cartridge-and-reader architecture must also meet that regulation for design controls, risk management (ISO 14971), and software validation (IEC 62304) — all before the submission package lands at FDA. The agency's recent emphasis on strengthening U.S. pharmaceutical manufacturing and supply chain resilience extends to diagnostic device supply chains, meaning SiPhox's semiconductor fabrication partners and reagent sourcing will face scrutiny during establishment registration and inspection.

Clinical validation for dozens of biomarkers multiplies the study burden. Each analyte requires precision, accuracy, linearity, and interference testing across the claimed measuring range, plus method comparison against central-lab reference methods. The FDA expects clinical studies in the intended-use population (consumers self-testing at home) with predefined acceptance criteria for sensitivity and specificity per biomarker. A single pivotal study powering many endpoints is statistically complex; the agency may require tiered endpoints or a phased clearance strategy where a subset of high-value markers clears first. SiPhox's MIT News profile noted the chip's integration of hundreds of optical components on a CMOS-compatible process, but the regulatory file must translate that engineering density into per-analyte performance data the FDA can review independently.

These requirements directly shape hiring. SiPhox needs regulatory affairs professionals fluent in De Novo strategy and CDRH pre-submission engagement (Q-Sub program) to negotiate study designs before enrollment. Quality engineers must build a Part 820-compliant quality management system covering design history files, device history records, and complaint handling, scaled for a product combining photonics, microfluidics, and reagent chemistry. Clinical affairs hires will design and oversee the pivotal studies, while human factors specialists run the formative and summative usability tests the FDA mandates for home-use claims. Biostatisticians enter the picture to structure the multiplicity-adjusted statistical analysis plans for correlated endpoints. None of these roles are optional; the FDA's refusal-to-accept checklist for De Novo submissions rejects incomplete quality system or clinical data packages at the threshold.

The timeline compresses further when accounting for FDA review cycles. A De Novo request targets 150 FDA review days but typically triggers multiple deficiency letters, each adding 180-day applicant response clocks. The Series A funds the engineering, but the regulatory headcount buildout determines whether the capital converts to a cleared product or a stalled submission.

Incumbents Dig In

Everlywell and LetsGetChecked have spent years building the at-home testing category on a simple model: mail a kit, collect a sample, send it to a CLIA-certified lab, get results in days. SiPhox's silicon photonics chip, capable of measuring many biomarkers from a home-collected sample and pursuing FDA clearance, upends that model. The incumbents are not standing still.

Everlywell, founded in 2015 and headquartered in Austin, has expanded from standalone test kits into a platform play. Its Everlywell+ subscription locks in one free qualifying test per month plus a 20 percent discount on additional kits, a recurring-revenue moat SiPhox lacks. The company has layered on high-margin partnerships spanning multi-cancer screening, early detection, microbiome analysis, and rapid PCR STI testing (see table). These additions push Everlywell beyond wellness into clinical-grade screening, directly contesting the "lab-quality at home" narrative SiPhox plans to own. Everlywell also operates four in-person sexual health tests through Quest Diagnostics patient service centers, a hybrid collection network SiPhox cannot yet match. Its mobile app handles kit registration, shipment tracking, and result delivery, a consumer experience layer SiPhox will need to replicate or exceed. Notably, Everlywell still ships to only 49 states; New York's regulatory barrier excludes it, a gap SiPhox could exploit if its FDA pathway clears national distribution.

LetsGetChecked, with a 14-test menu (see table) and a two-to-five-day turnaround, has pursued a different vector: hereditary cancer screening. Its newly launched Comprehensive Hereditary Cancer Solution targets a high-value clinical niche SiPhox's broad wellness panel does not yet address. Neither competitor has FDA clearance for their core at-home panels; both rely on CLIA certification of their processing labs. SiPhox's regulatory strategy, if successful, creates a categorical differentiator: a cleared device versus a lab-developed test framework.

This competitive pressure shapes SiPhox's priorities. Product differentiation roles must articulate why dozens of analytes on one chip beats a menu of single-analyte kits. Market access hires face a landscape where Everlywell's subscription model and Quest-partnered phlebotomy network set expectations for convenience and coverage. Commercial hires need to counter Everlywell's brand recognition (11 years, millions of kits sold) and LetsGetChecked's clinical partnerships. Software and UX roles must deliver an app experience at parity with Everlywell's tracking and results interface. Regulatory and quality engineering hires, already critical for the FDA submission, gain urgency: every month of delay lets incumbents deepen their moats.

The incumbents' moves confirm the market validates SiPhox's direction — multi-analyte, rapid, at-home — while raising the bar for execution.

The Chip That Could Rewrite the Category

Vermeulen's millimeter of silicon sits in Burlington today, with validation studies planned that will eventually land on FDA reviewers' desks. The same CMOS fabs that once powered the internet's backbone now churn out cartridges at 10,000 a month — each one a disposable lab, each one a bet that the basement-sized analyzer can stay in the basement. If the De Novo submission succeeds, the first consumer reads cholesterol, cortisol, CRP, testosterone, vitamin D, and dozens of other markers from a home-collected sample before coffee finishes brewing. Everlywell's subscription renews. LetsGetChecked's phlebotomist drives to the next house. And the engineering expansion that started with a Series A becomes the workforce that ships chips at scale.

Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.